Roche

Roche's CT-388 is a once-weekly dual GLP-1/GIP receptor agonist acquired through the 2023 Carmot Therapeutics deal. Phase 1 data in early 2024 showed ~19% mean weight loss at 24 weeks, putting CT-388 in the same potency bracket as tirzepatide. Roche has prioritized a faster-than-typical Phase 2/3 progression to compete on time-to-market with Lilly and Amgen.

Roche also has CT-996 (oral small-molecule GLP-1) and an early-stage amylin program from the Carmot acquisition. The company's position is that the obesity space is large enough for multiple molecules and that mechanistic differences between GLP-1/GIP/glucagon/amylin combinations will produce meaningfully different clinical profiles for different patient subpopulations.

The RHHBY ticker is the US OTC ADR; the primary listing is ROG.SW on SIX Swiss Exchange. We use RHHBY here so the live ticker renders in the same timezone as the rest of the directory.